---
search:
  boost: 2 
---

# Glaucoma Agents

This is a subcategory of Ophthalmic Agents.

## Decision Trees

- [Glaucoma Agents- Non-Preferred - Apraclonidine, Betoptic S, Bimatoprost, Brimonidine 0.15%, Brinzolamide, Iopidine, Istalol, Lumigan, Travoprost*, Vyzulta, Xelpros, Zioptan](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?origin=OfficeDotCom&lang=en-US&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURFlFT0ZNMUxFV0tITEdERjYxOFMxTExZSCQlQCN0PWcu&topview=Preview)
- [Glaucoma Agents- Preferred (Step Therapy) - Azopt, Combigan, Travatan Z](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?origin=OfficeDotCom&lang=en-US&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQkJQSzVNNjBIU0tXN1NTNTFaNDFYM0k1NyQlQCN0PWcu&topview=Preview)

## Formulary

### Preferred

| Preferred                       | Generic Name | Quantity | Time (Days) |
|:--------------------------------|:-------------|:--------:|:-----------:|
| Alphagan P 0.1%                 |              |          |             |
| Alphagan P 0.15% <sup>BvG</sup> |              |          |             |
| Azopt <sup>BvG ST</sup>         |              |          |             |
| Betaxolol                       |              |          |             |
| Betaxolol                       |              |          |             |
| Brimonidine 0.2%                |              |          |             |
| Carteolol                       |              |          |             |
| Combigan <sup>BvG ST</sup>      |              |          |             |
| Dorzolamide                     |              |          |             |
| Dorzolamide / Timolol           |              |          |             |
| Latanaprost                     |              |          |             |
| Levobunolol                     |              |          |             |
| Metipranolol                    |              |          |             |
| Rhopressa                       |              |          |             |
| Rocklatan                       |              |          |             |
| Simbrinza                       |              |          |             |
| Timolol 0.5% Gel, Soln          |              |          |             |
| Travatan Z <sup>BvG ST</sup>    |              |          |             |

### Non-Preferred

| Non-Preferred                 | Generic Name | Quantity | Time (Days) |
|:------------------------------|:-------------|:--------:|:-----------:|
| Apraclonidine                 |              |          |             |
| Betoptic S                    |              |          |             |
| Bimatoprost                   |              |          |             |
| Brimonidine 0.15%             |              |          |             |
| Brinzolamide                  |              |          |             |
| Iopidine                      |              |          |             |
| Istalol                       |              |          |             |
| Lumigan                       |              |          |             |
| Timoptic 0.25% <sup>BvG</sup> |              |          |             |
| Travoprost                    |              |          |             |
| Vyzulta                       |              |          |             |
| Xelpros                       |              |          |             |
| Zioptan <sup>BvG</sup>        |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug in the same class, if available

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs in the same class, if available
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=88)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=29)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
